Article
Biochemistry & Molecular Biology
Chao Liu, Yining Li, Ren Sheng, Xiaowan Han, Li Bao, Chenyin Wang, Weizhi Wang, Xinhai Jiang, Jiangxue Han, Lijuan Lei, Ni Li, Jing Zhang, Minghua Chen, Yan Li, Yexiang Wu, Shunwang Li, Yu Ren, Yanni Xu, Shuyi Si
Summary: The study demonstrated that the N-methylpyridine-chlorofuranformamide analog 3i1 shows promise in upregulating OPG activity, inhibiting RANKL-induced osteoclastogenesis, and promoting osteoblast differentiation, potentially serving as a new therapeutic agent for osteoporosis.
BIOORGANIC CHEMISTRY
(2021)
Article
Plant Sciences
Xiangmin Ni, Bin Wu, Shuo Li, Wenyi Zhu, Zhe Xu, Guiming Zhang, Hanqiang Cui, Qian Bai, Jian Wang
Summary: Eq, as a metabolite of soy isoflavones, has a therapeutic effect on PMOP by promoting osteoblast proliferation, inhibiting apoptosis, and upregulating the OPG/RANKL pathway.
Article
Biochemistry & Molecular Biology
Jung Ha Kim, Kabsun Kim, Inyoung Kim, Semun Seong, Hyun Kook, Kyung Keun Kim, Jeong-Tae Koh, Nacksung Kim
Summary: CrkL regulates the coupling signals between osteoblasts and osteoclasts by decreasing RANKL expression, which plays a crucial role in bone homeostasis by inhibiting both osteoblast-dependent osteoclast differentiation and osteoclast-dependent osteoblast differentiation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Tommy W. Sutor, Jayachandra Kura, Alex J. Mattingly, Dana M. Otzel, Joshua F. Yarrow
Summary: Spinal cord injury causes paralysis and osteoporosis, increasing fracture risk. Physical rehabilitation regimens for patients with severe SCI have limited evidence in influencing bone metabolism or increasing bone mineral density.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Hyo Shik Shin, Hyun Jin Sun, Young Mi Whang, Young Joo Park, Do Joon Park, Sun Wook Cho
Summary: Metformin significantly reduced the viabilities of thyroid cancer cells and delayed tumor growth in bone metastasis. In the microenvironment of bone metastasis, metformin inhibited cancer cell growth, blocked cancer cell-induced osteoblastic RANKL production, which further activated osteoclastogenesis, and directly reduced osteoclast differentiation.
Review
Endocrinology & Metabolism
Nobuyuki Udagawa, Masanori Koide, Midori Nakamura, Yuko Nakamichi, Teruhito Yamashita, Shunsuke Uehara, Yasuhiro Kobayashi, Yuriko Furuya, Hisataka Yasuda, Chie Fukuda, Eisuke Tsuda
Summary: Osteoclasts and osteoblasts play essential roles in bone remodeling, with the regulation of RANKL and OPG expression being a key mechanism. The balance between these factors is crucial for maintaining bone density and preventing bone loss.
JOURNAL OF BONE AND MINERAL METABOLISM
(2021)
Review
Endocrinology & Metabolism
Jing-Yi Xue, Shiro Ikegawa, Long Guo
Summary: The RANKL/OPG/RANK signaling pathway plays a crucial role in bone metabolism and genetic mutations in associated genes can lead to various skeletal disorders. These disorders can be categorized into two types based on their effects on osteoclast formation and bone density.
JOURNAL OF BONE AND MINERAL METABOLISM
(2021)
Article
Multidisciplinary Sciences
Dane Huang, Chao Zhao, Ruyue Li, Bingyi Chen, Yuting Zhang, Zhejun Sun, Junkang Wei, Huihao Zhou, Qiong Gu, Jun Xu
Summary: This study reports an approach to identify selective and druggable binding sites on protein surfaces for designing anti-osteoporotic drugs. A specific binding site was discovered that allows disruption of a particular protein interaction without interfering with other related interactions. The developed inhibitor demonstrates specificity and anti-osteoporotic effects through in vitro and in vivo studies.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Junjie Lu, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, Bo Shuai
Summary: Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits bone resorption by competitively binding with RANKL and blocking the activation of the RANK/RANKL/OPG signaling pathway. It is used to treat metabolic bone diseases and has potential in the treatment of osteoarthritis, bone tumors, and other autoimmune diseases. However, more research is needed to understand its mechanism of action and optimize its clinical use for bone metastasis of malignant tumors.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Gabriel Bassan Marinho Maciel, Roberto Marinho Maciel, Cristiane Cademartori Danesi
Summary: This work summarizes the characteristics of bone cells involved in physiological bone remodeling. Remodeling is a distinct process from modeling, and it allows the renewal of old or damaged bone tissue to maintain bone fracture resistance and calcium and phosphorus homeostasis. The role of osteoclasts, osteoblasts, osteocytes, and bone lining cells in bone remodeling is addressed, and the regulation of bone remodeling through hormones and growth factors is discussed. Understanding physiological bone remodeling is essential for studying bone-related pathologies and developing new therapies.
MOLECULAR BIOLOGY REPORTS
(2023)
Article
Cell Biology
Sofia Passaponti, Leonardo Ermini, Giulia Acconci, Filiberto Maria Severi, Roberta Romagnoli, Santina Cutrupi, Marinella Clerico, Gisella Guerrera, Francesca Ietta
Summary: This study demonstrates the influence of late pregnancy on the balance between RANKL and OPG in women with multiple sclerosis (MS), and identifies the placenta as an important source of homodimeric OPG. Placental OPG suppresses the mRNA expression of CCL20 and affects the recruitment of Th17 cells. Therefore, placental OPG may play a crucial role in the beneficial effects of late pregnancy on MS, and could potentially be used for the development of new and more effective therapeutic approaches.
Article
Microbiology
Jiah Yeom, Seongho Ma, Young-Hee Lim
Summary: The study found that Propionibacterium freudenreichii MJ2 isolated from raw milk can enhance osteoblast differentiation and mineralization through the OPG/RANKL signaling pathway. The surface proteins of MJ2 may be the effective component in promoting osteoblast differentiation and mineralization.
Review
Biochemistry & Molecular Biology
Meng Chen, Wenyu Fu, Huiyun Xu, Chuan-ju Liu
Summary: Glucocorticoid (GC) is commonly used to treat inflammatory and autoimmune diseases, but its high doses and long-term usage can lead to adverse effects, especially glucocorticoid-induced osteoporosis (GIO). Excessive GCs have harmful effects on bone cells, inhibiting osteoblast proliferation and differentiation, enhancing osteoblast and osteocyte apoptosis, and promoting osteoclastogenesis and bone resorption. GCs also disrupt the secretion of bone cells, affecting the process of osteoblastogenesis and osteoclastogenesis.
CYTOKINE & GROWTH FACTOR REVIEWS
(2023)
Review
Endocrinology & Metabolism
Yan Zhang, Jingqi Liang, Peilong Liu, Qiong Wang, Liang Liu, Hongmou Zhao
Summary: With the increasing incidence of cancer, tumor bone metastasis has become more common among patients. The RANK/RANKL/OPG system and osteoclasts play important roles in bone homeostasis and tumor bone metastasis formation, and inhibiting this system can prevent metastasis.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biology
Lisha Li, Jing Zhou, Yingping Xu, Zengshu Huang, Na Zhang, Xuemin Qiu, Ling Wang
Summary: Inflammatory factors affect osteoblast and osteoclast activity in osteoporosis, and estrogen plays a role in bone metabolism through CCR6 signaling pathways. The study showed that CCR6 deletion reduced osteoblast activity and mineralization, while also influencing the expression of Osterix and RANKL, potentially regulating bone metabolism.